US paus­es dis­tri­b­u­tion of GSK/Vir's Covid mAb not due to Omi­cron, but greater sup­ply of Eli Lil­ly mAbs

The US gov­ern­ment is shift­ing its dis­tri­b­u­tion of mAb in­fu­sions to fight the coro­n­avirus, de­cid­ing to go from sup­ply­ing tens of thou­sands of dos­es of Glax­o­SmithK­line and Vir’s mAb treat­ment sotro­vimab in re­cent months to ze­ro dos­es for the en­tire month of De­cem­ber.

That halt has led to spec­u­la­tion the gov­ern­ment was pri­or­i­tiz­ing the dis­tri­b­u­tion of Re­gen­eron mAb com­bo of casiriv­imab and imde­vimab and Eli Lil­ly’s com­bo of bam­lanivimab and ete­se­vimab be­cause both com­pa­nies have in­di­cat­ed that their in­fu­sions might not work as well against the Omi­cron vari­ant (when com­pared to Delta).

But an HHS spokesper­son said the rapid rise of the Omi­cron vari­ant was not the cause for this pause in sotro­vimab ship­ments.

“We tem­porar­i­ly paused dis­tri­b­u­tion of sotro­vimab in or­der to uti­lize more of the bam­lanivimab/ete­se­vimab prod­uct, of which we have greater sup­ply and be­cause the prod­uct re­cent­ly re­ceived an ex­pand­ed FDA emer­gency use au­tho­riza­tion to now in­clude pe­di­atric pa­tients,” an HHS spokesper­son said. “We will con­tin­ue to as­sess the COVID-19 en­vi­ron­ment and ad­just prod­uct dis­tri­b­u­tion ac­cord­ing­ly.”

Lil­ly said in a state­ment that it has been ramp­ing up ship­ments over the past three months. In ear­ly No­vem­ber, the com­pa­ny said it signed a $1.29 bil­lion deal to sup­ply more than 600,000 dos­es of the bam­lanivimab with ete­se­vimab com­bo, by no lat­er than Jan. 31, 2022.

In­evitably the Omi­cron vari­ant may end up caus­ing the fed­er­al gov­ern­ment to pri­or­i­tize sotro­vimab again as lab stud­ies in­di­cate GSK and Vir’s mAb may fair bet­ter against the Omi­cron vari­ant than Re­gen­eron or Lil­ly, al­though its ef­fi­ca­cy will like­ly still de­cline. GSK de­clined to com­ment on the gov­ern­ment’s dis­tri­b­u­tion plan.

The FDA is al­so like­ly to of­fer its take on the vari­ant sit­u­a­tion, as the agency in March up­dat­ed its fact sheets on the Eli Lil­ly and Re­gen­eron mAbs, pro­vid­ing new da­ta on how they fared against the pre­vi­ous vari­ants orig­i­nat­ing in the UK, Brazil, South Africa, Cal­i­for­nia and New York.

GSK and Vir, which said last week that their mAb main­tains its ef­fi­ca­cy against Omi­cron, turned over the dis­tri­b­u­tion of their mAb to the US gov­ern­ment in Oc­to­ber af­ter strik­ing a near­ly $280 mil­lion pro­cure­ment deal.

Forge Bi­o­log­ics’ cGMP Com­pli­ant and Com­mer­cial­ly Vi­able Be­spoke Affin­i­ty Chro­matog­ra­phy Plat­form

Forge Biologics has developed a bespoke affinity chromatography platform approach that factors in unique vector combinations to streamline development timelines and assist our clients in efficiently entering the clinic. By leveraging our experience with natural and novel serotypes and transgene conformations, we are able to accelerate affinity chromatography development by nearly 3-fold. Many downstream purification models are serotype-dependent, demanding unique and time-consuming development strategies for each AAV gene therapy product1. With the increasing demand to propel AAV gene therapies to market, platform purification methods that support commercial-scale manufacturing of high-quality vectors with excellent safety and efficacy profiles are essential.

Mathai Mammen, FogPharma's next CEO

Math­ai Mam­men hands in J&J's R&D keys to lead Greg Ver­dine’s Fog­Phar­ma 

In the early 1990s, Mathai Mammen was a teaching assistant in Greg Verdine’s Science B46 course at Harvard. In June, the former R&D head at Johnson & Johnson will succeed Verdine as CEO, president and chair of FogPharma, the same month the seven-year-old biotech kickstarts its first clinical trial.

After leading R&D at one of the largest drugmakers in the world, taking the company through more than half a dozen drug approvals in the past few years, not to mention a Covid-19 vaccine race, Mammen departed J&J last month and will take the helm of a Cambridge, MA biotech attempting to go after what Verdine calls the “true emperor of all oncogenes” — beta-catenin.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

Sen­ate Fi­nance Com­mit­tee lobs more bi­par­ti­san pres­sure on­to PBMs

Congress is honing in on how it wants to overhaul the rules of the road for pharmacy benefit managers, with a Senate Finance Committee hearing Thursday serving as the latest example of the Hill’s readiness to make changes to how pharma middlemen operate.

While pledging to ensure patients and pharmacies “don’t get a raw deal,” Finance Committee Chair Ron Wyden (D-OR) laid out the beginning of what looks like a major bipartisan effort — moves the PBM industry is likely to challenge vigorously.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

Nicklas Westerholm, Egetis Therapeutics CEO

Ac­qui­si­tion talks on­go­ing for Swedish rare dis­ease biotech Egetis, shares up al­most 40%

Shares of the Sweden-based rare disease biotech Egetis Therapeutics skyrocketed on Thursday afternoon as the company said it’s engaged in “ongoing discussion” with external parties regarding a “potential acquisition.”

Egetis confirmed rumors with a statement on Thursday while noting that there is no certainty that a takeover offer will be made.

Nonetheless, the possibility of an acquisition has shot up Egetis’ share price. By the afternoon on Thursday, its stock price was {$EGTX.ST} up over 38%. An Egetis spokesperson told Endpoints News in an email that it has no further comments.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

Lu­pus drug de­vel­op­ment mar­ket heat­ing up, while FDA links with ad­vo­ca­cy group to fur­ther ac­cel­er­ate re­search

The long-underserved systemic lupus erythematosus (SLE) market is suddenly buzzing with treatment possibilities. Less than two years after AstraZeneca’s approval for Saphnelo — the first new SLE drug in a decade and joining just one other approved in GSK’s Benlysta – the pipeline of potential drugs numbers in the dozens.

Although most are very early stage — Spherix Global Insights estimates five in Phase II/III — the pharma R&D enthusiasm is catching on among doctors, patients and advocacy groups. On Wednesday, the Lupus Research Alliance and the FDA formed a novel private-public partnership called Lupus Accelerating Breakthroughs Consortium (Lupus ABC) to help advance lupus clinical trial success.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel, Moderna CEO (AP Photo/Markus Schreiber)

Mod­er­na so­lid­i­fies deal with Kenya to build mR­NA man­u­fac­tur­ing fa­cil­i­ty

The mRNA player Moderna is further cementing its presence on the African continent.

Moderna announced on Thursday that it has finalized an agreement with Kenya’s government to partner up and bring an mRNA manufacturing facility to the east African nation. The new facility aims to manufacture up to 500 million doses of vaccines annually. Moderna also said the new facility will have the ability to spike its production capabilities to respond to public health emergencies on the continent or globally.

Luke Miels, GSK chief commercial officer

GSK picks up Scynex­is' FDA-ap­proved an­ti­fun­gal drug for $90M up­front

GSK is dishing out $90 million cash to add an antifungal drug to its commercial portfolio, in a deal spotlighting the pharma giant’s growing focus on infectious diseases.

The upfront will lock in an exclusive license to Scynexis’ Brexafemme, which was approved in 2021 to treat a yeast infection known as vulvovaginal candidiasis, except in China and certain other countries where Scynexis already out-licensed the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.

Deborah Waterhouse, ViiV Healthcare CEO

MPP re­cruits three gener­ic man­u­fac­tur­ers to ex­pand use of Vi­iV's in­jectable PrEP drug

ViiV Healthcare has teamed up with the UN-backed Medicines Patent Pool and three generic manufacturers to expand access to medicine that can prevent HIV.

ViiV and the Medicines Patent Pool jointly announced Thursday that the MPP signed sub-licensing agreements with Aurobindo, Cipla and Viatris to manufacture generics of a long-acting form of cabotegravir for HIV pre-exposure prophylaxis (PrEP). As a result of the agreement, the manufacturers will be able to develop, manufacture and supply generic versions of cabotegravir LA in 90 countries — subject to regulatory approvals.

Four community leaders who are living with HIV celebrate life and accomplishments in Theratechnologies' new campaign

Re­al pa­tient ‘cham­pi­ons’ liv­ing with HIV star in Ther­at­e­ch­nolo­gies cam­paign

Over the past several years, people living with HIV have been more often telling Theratechnologies that they wanted more representation. Specifically, they wanted more African American people and more focus on living and thriving versus more typical medication regimen messaging.

So Theratechnologies came up with a new campaign called “I Am A Champion,” initially launched at the US Conference on HIV last year. The initial conference, print and digital media efforts highlight the triumphs of four long-term survivors from across the US.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.